Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

ional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

(Tables to follow)GenVec
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
2. GenVec Appoints Cynthia Collins as President and CEO
3. GenVec Reports Inducement Award
4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
6. GenVec Reports Second Quarter 2012 Financial Results
7. GenVec Reports Third Quarter 2012 Financial Results
8. GenVec to Present at 25th Annual ROTH Conference
9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  The Healthcare Analytics Summit 2014 ... Salt Lake City , Sept. 24-25 ... respected healthcare organizations in the U.S. and beyond.  HAS ... industry conference devoted to providing immersive learning experiences on ... of both accountable care initiatives and population health ...
(Date:7/29/2014)... IRVING, Texas , July 29, 2014 /PRNewswire/ ... three new web-based applications with breakthrough interactive features ... and workflows for members of Children,s Hospital Association.  ... under the Novation Optimize Solutions umbrella – Value ... of how Novation helps organizations address the most ...
(Date:7/29/2014)... DIEGO , July 29, 2014   ... Nancy Thornberry to its board of ... franchise head, Diabetes and Endocrinology for Merck & ... strategy and overall pipeline management in diabetes, osteoporosis, ... initiated and co-led the program that resulted in ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Research, TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- ... that,(1) demonstrate that Azixa(TM) (MPC-6827) is effective in ... (2) reveal a,mechanism by which MPC-6827 exerts its ... by cellular proteins known to be involved,in cancer ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... improvement measures in eight of the 10 hospitals in ... have found a way to reduce kidney injury in ... 7-15 percent of these patients who undergo a coronary ... which can result in death or rapid decline in ... a study published in the July issue of ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... Avenidas is always looking for ways to ... non-profit agency is doing just that with the Third Annual ... event gives seniors the opportunity to learn about how they ... a variety of fun activities, including a Tai Chi demonstration, ... In addition, there will be food tastings, courtesy of Lyfe ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... - Researchers from the Boston University School of Medicine ... a $3.5 million grant from the National Institute on ... treat, and retain" paradigm in Eastern Europe among HIV-infected ... narcology (addiction) care. The project will be known as ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... Mozes HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... people to develop cancer, new British research says. Among ... leukemia or melanoma appears to go up about 16 percent ... "Taller women in our study had increased risk of a ...
... , THURSDAY, July 21 (HealthDay News) -- A new U.S. ... to use the Internet for medical information, and whites are ... the findings released Thursday by the U.S. National Center for ... as likely as Hispanics to search for health information online. ...
... National Nanotechnology Initiative,s (NNI) released four reports that ... focusing on various issues in the nanotechnology environmental, ... series was a part of an ongoing strategy ... from industry, academia, and the Federal Government to ...
... the first time created a way of measuring how much force ... advance is expected to have significant implications for legal forensics. ... the force applied during a stabbing and come up with the ... work has been published in the International Journal of Legal ...
Cached Medicine News:Health News:BUSM/BMC researchers awarded $3.5 million grant from the NIDA 2Health News:Minority participants crucial to effective aging studies 2Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Women, Whites Most Likely to Seek Health Info Online: Survey 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 3
... offers the ease and comfort you've come to ... users in clinical trials agreed that the BD ... depth settings allow you to choose the best ... of lancets, the device also helps eliminate the ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
... The StaRRsed Compact is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: